Trade Virpax Pharmaceuticals, Inc. - VRPX CFD

Trading Conditions

• Spread: 0.15
• Long position overnight feeLong position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position-0.026179 %(-$1.05)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position0.003957 %($0.16)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-$1.05)

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  ($0.16)

Key Stats

• Prev. Close: 2.73
• Open: 2.72
• 1-Year Change: 294.2%
• Day's Range: 2.59 - 2.8

Virpax Pharmaceuticals, Inc. Company profile

Founded in 2016, Virpax Pharmaceuticals (VRPX) is a preclinical stage biopharmaceutical company that develops and manufactures novel and proprietary drug delivery systems for non-opioid and non-addictive pain treatments.

Based in Berwyn, Pennsylvania, US, Virpax has global rights to the following patented pain management technologies:

• Epoladerm – A topical nonsteroidal anti-inflammatory drug candidate for treatment of chronic osteoarthritis of the knee. It is used once a day.

• Probudur – Injectable local anaesthetic Lipoal Gel Technology for postoperative pain management. The company plans to market this drug candidate to general surgeons, anesthesiologists and orthopaedic surgeons with the local anaesthetic postsurgical market, valued at $577m (£451m) as of 2019. The company believes Probudur can eliminate the need for opioids for postoperative pain relief.

• Envelta – A Molecular Envelope Technology (MET) that delivers enkephalin for the management of acute and chronic pain, including cancer-induced pain, using an intranasal device. Virpax has identified a significant unmet need and market opportunity for current opioid prescribers, such as pain and hospice treatment centres.

• AnQlar – A nasal spray that is being developed as an anti-viral barrier to potentially prevent or reduce the severity of viral infections in humans. The company has completed toxicology and ex-vivo studies on AnQlar, which show a reduction in infectivity from respiratory viruses such as influenza and SARS-CoV-2.

• VRP324 – An investigational formulation designed to improve cannabidiol (CBD) transport to the brain via the nasal route. VRP324 propels the CBD powder formulation into the nose and into the brain via the olfactory nerve/bulb using a preassembled device and cartridge. This product candidate can potentially treat seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in patients aged one year and older. CBD is a substance found in cannabis.

Virpax went public on 16 February 2021. Its stock is listed on the Nasdaq capital market under the ticker symbol ‘VRPX’.